Oxford Pharmascience Group Share News (OXP)

Oxford Pharmascience Posts Widened Loss As It Ups Investment

Oxford Pharmascience Progressing Low Gastric-Irritation Naproxen

Oxford Pharmascience Agrees Inellare Extension With Brazil's Aché

LONDON (Alliance News) - Oxford Pharmascience Group PLC Tuesday said it has agreed a line extension with Brazilian pharmaceuticals partner Aché Pharmaceuticos, for a new version of the calcium and vitamin D chew tablet Inellare. The specialty pharmaceutical company said sales of the new ver

Oxford Pharmascience Sees Positive OXP001 Study Results

LONDON (Alliance News) - Oxford Pharmascience Group PLC said Monday that it had seen positive results from a pilot clinical study of its reduced gastric irritation ibuprofen product OXP001. The proof of concept clinical study was to determine the extent of upper gastrointestinal irritation

Oxford Pharmascience Appoints Research Firm For Safestat Pilot Study

LONDON (Alliance News) - Oxford Pharmascience Group PLC said Wednesday it has appointed Quotient Clinical to undertake its early clinical development programme for its OXP003 Safestat product proof of concept study. The specialty pharmaceutical firm said it has appointed the company to unde

Carnival Chairman reduces stake by around a quarter

Micky Arison, the long-standing Chairman of cruise line operator Carnival Corp., docked a batch of shares earlier this week ahead of its better-than-expected first quarter trading update. Arison offloaded 525,348 at $40.09 each, reducing his stake to 104.52m shares. The group on Tuesday reported

DIRECTOR DEALINGS: Oxford Pharmascience Chair Buys 1 Million Shares

LONDON (Alliance News) - Oxford Pharmascience Group PLC Wednesday said Non-Executive Chairman David Norwood bought 1 million shares at a price of 4.3 pence per share Tuesday. Following this transaction, Norwood now holds 106 million shares, which represents 10.62% stake in the firm. S

Oxford Pharmascience Group Appoints R&D Head

LONDON (Alliance News) - Oxford Pharmascience Group PLC said Monday it has appointed a Director of research and development to manage the firms' development activities. Dr Liz King has joined to lead and execute the company's development programme focused on the company's two main medicines

Oxford Pharmascience Starts Dosing Subjects In Ibuprofen Study

LONDON (Alliance News) - Oxford Pharmascience Group PLC Monday said it has begun dosing subjects in the pilot clinical study of its OXP001 400 milligram Ibuprofen treatment. The company redevelops existing medicines to try and make them better, safer and easier to take and is trying to dev

Oxford Pharmascience Pretax Loss Widens, New CEO Appointed

LONDON (Alliance News) - Oxford Pharmascience Group PLC Wednesday said it appointed a new chief executive and saw a widened pretax loss in 2013 due to increased research and development costs, as it advanced its product programmes towards commercialisation. The pharmaceutical technology com

Oxford Pharmascience Gets Approval For Ibuprofen Product Trial

LONDON (Alliance News) - Oxford Pharmascience Group PLC Friday said its clinical trial application for OXP001 400 milogram reduced gastric irritation Ibuprofen has received approval from the UK Medicines and Healthcare Products Regulatory Agency and the Ethics Review Committee. The company,

Oxford Pharmascience Brazilian Partner Launches Sugar-Free Vitamin Chew

AIM IN BRIEF: Chamberlin Swings To Half-Year Loss, Suspends Dividend

Oxford Pharmascience Raises GBP4M Through 100M Share Placing

Oxford Pharmascience Completes Ibuprofen Formulation